Grifols SA
Research Grifols SA (GRFS) on Bullrun: valuation model: 40.4% undervalued, market cap USD 1.93B, P/E 9.6, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRFS
- ExchangeNASDAQ
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal40.4% undervalued
- Market capUSD 1.93B
- P/E9.6
- Dividend yield1.3%
- Financial periodQ2 2026
- RevenueEUR 1.87B
- Net incomeEUR 154.00M
- Free cash flowEUR 108.00M
- Gross margin37.6%
Valuation Snapshot
Bullrun's latest valuation model marks Grifols SA as 40.4% undervalued; latest market cap is USD 1.93B; P/E is 9.6; dividend yield is 1.3%.
Peer valuation comparison
Latest P/E is 9.63x versus a Healthcare sector median of 24.61x (60.9% below).
Latest dividend yield is 1.28% versus a Healthcare sector median of 1.84% (30.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 7.52B | EUR 402.00M | EUR 624.00M | 38.0% | 0.59 | EUR 801.00M | EUR 9.57B | EUR 5.27B |
| FY2024 | EUR 7.21B | EUR 157.00M | EUR 530.00M | 38.7% | 0.23 | EUR 980.00M | EUR 10.11B | EUR 5.88B |
| FY2023 | EUR 6.59B | EUR 42.00M | -EUR 93.00M | 37.7% | 0.09 | EUR 529.58M | EUR 10.97B | EUR 5.37B |
| FY2022 | EUR 6.06B | EUR 185.04M | -EUR 394.30M | 36.5% | 0.31 | EUR 549.21M | EUR 9.75B | EUR 5.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.93B | 9.6 | 1.3% | 0.09 |
| 2025 | 2025-12-31 | USD 6.36B | 14.0 | 1.8% | 0.17 |
| 2024 | 2024-12-31 | USD 5.06B | 29.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.84B | 32.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.77B | 8.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.62B | 11.6 | 4.1% | 0.46 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.09 USD, yield 1.3%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.17 EUR |
About Grifols SA
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Grifols SA overvalued or undervalued?
Bullrun's valuation model currently marks Grifols SA as 40.4% undervalued.
What is Grifols SA's market cap?
Grifols SA's market capitalization is USD 1.93B.
What is Grifols SA's P/E ratio?
Grifols SA's price-to-earnings (P/E) ratio is 9.6.
Does Grifols SA pay a dividend?
Grifols SA has a dividend yield of 1.3%.
What does Grifols SA do?
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.